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ABSTRACT 
Over the last few years, there has been a significant consideration of solid lipid nanoparticles (SLNs) as an alternative method to other colloidal 
dispersion methods for drug delivery. Special consideration has been given to the use of SLNs as a drug carrier in recent years. SLNs are aqueous 
dispersions in which the colloidal particles consist of solid lipids that are biodegradable. As a result of their physical stability, the protection of the 
entrapped drug from decomposition, the provision of controlled drug release, and the exceptional acceptability, SLNs have several advantages over 
other drug carriers. This article focuses on the techniques of SLNs preparation and characterization, the effect of formulation variables on SLNs 
properties, the routes of administration, and the pharmaceutical applications. The data used for this review was collected by searching on Google 
Scholar and PubMed using the following keywords during the period from 2010 to date. 
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INTRODUCTION 
Novel drug delivery systems are rapidly developing as a result of the 
success achieved in disciplines such as biomedical engineering, 
biotechnology, and nanotechnology. Several methods of preparation 
are used nanotechnology in the production of Nano-sized structures. 
In pharmacy, the aim of nanotechnology is to prepare drugs in the 
form of nanoparticles, which can be effectively absorbed, resulting in 
giving a pharmacological response with minimum side effects via a 
controlled drug release method [1]. As colloidal particles, SLNs are 
made up of solid lipids with a very high melting point forming a solid 
base covered by a hydrophilic surfactant. The use of solid lipid as a 
drug carrier is highly recognized by lipid pellets for oral drug 
transportation [2]. Lipids, which include glycerides, waxes, fat, oil, 
triglycerides, and hard fat, are used in the preparation of SLNs. They 
provide advantages for SLNs as a result of the lipid matrix consisting 
of physiological lipids with a low hazard of severe and chronic 
toxicity. It was reported that the solid lipid increases the controlled 
release properties and enhances the chemical stability of entrapped 
drugs. These advantages of solid lipid over liquid lipid can be 
attributed to the physicochemical properties associated with the 
physical condition of the lipid state [3]. Several studies have 
reported the use of a solid lipid in the preparation of SLNs instead of 
a liquid lipid, which allows the slow digestion of the nanoparticles 
resulting in the continued release of the entrapped drugs. Aqueous 
surfactants are other main excipients of SLNs. They act as an 
emulsifier to produce o/w emulsion and as a stabilizer for the 
dispersion of SLNs. Their selection depends primarily on the route of 
application. Generally, SLNs are prepared by a solid lipid from which 
the drug is dissolved or diffused [4]. 
The effect of formulation variables on the properties of SLNs 
For the construction of any drug transport scheme, excipients are 
vital and have the foremost part in defining product standards and 
efficiency [5]. 
 The effect of lipid  
The effect of lipid type on the properties of SLNs was observed by 
the hot homogenization method. A lipid with a high melting point 
was reported to form SLNs with a large size due to the higher 
viscosity of the diffused phase. Lipid hydrophobicity, lipid crystals 
forms, and lipid crystallization also represent factors which affect 
the SLNs’ properties [6]. Lipids are mixes of diverse compounds, and 
for this reason, their production may differ from a batch to another. 
In addition, the suppliers and such slight alterations of lipids can 
influence the quality of SLNs. Zeta potential, in vitro drug release, 
and particle size are the properties that are affected by the type of 
lipid. Chakraborty et al. reported that the increase in the lipid 
content over 5-10% would give rise to a larger particle size of 
SLNs [7]. 
 Effect of surfactant 
The properties of SLNs are greatly affected by the type of emulsifier. 
Any decrease in the surface tension and the particle size during 
preparation will be achieved when there is an increase in the 
quantity of emulsifier. Any decrease in the particle size will give rise 
to a large surface area. During the preparation of the primary 
dispersion of SLNs, an excess amount of surfactant should be added 
to cover the surfaces of the formed nanoparticles through High-
Pressure Homogenization [8]. The time required for the distribution 
of the surfactant between the surfaces of the prepared particles and 
micelles differs dependent on the type of surfactant. Previous 
studies revealed that the surfactants with low molecular weight take 
less time for redistribution, while surfactants with high molecular 
weight take a longer time to redistribute. When sodium 
glycocholate, a co-emulsifying agent, is added, it gives a further 
decrease in the size of the prepared nanoparticles [9]. 
The principle of drug release from SLN 
Ramteke et al. listed the following as the standards of drug release 
from lipid nanoparticles [10]: 
• A large surface area will result in a higher medication 
discharge due to little molecule measured in the nanometer.  
• If the drug is evenly spread in the lipid matrix, a slow 
medication discharge is achieved. 
• Fast medication release is obtained when the lipid carrier has a 
crystalline behaviour, and the drug has high portability. 
• The fast-drug release in the initial five minutes in the drug-
enriched shell model is due to the high surface area of the drug 
particles which are deposited on the surface. 
• The drug release decreases with the increase in the size of the 
particle, and sustained release can be attained when there are 
sufficient large particles (lipid macromolecules). 
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• The type and amount of the used surfactant existing in the 
outer shell of the SLNs have a significant effect on drug release. The 
small amount of surfactant can give rise to minimal burst and 
prolonged drug discharge. 
• The size of the particle and the drug release behavior are 
affected by several parameters such as SLN composition (drug, lipid, 
and surfactant), production technique, equipment, lyophilization, 
sterilization, and production time. 
SLN drug incorporation models  
The discharge of drug from SLN is explained through the following 
drug incorporation models (table 1 and fig. 1):  
 Homogenous matrix model or SLN Type I 
 Drug enhanced shell model or SLN Type II  
 Drug enhanced core model or SLN Type III 
  
Table 1: Different drug incorporation models in SLN 
SLN type I SLN type II SLN type III References  
Cold homogenization techniques are 
used to formulate this type 
Hot homogenization technique is used to 
formulate this type 
Cold dispersion allows super-saturation of 
the active ingredient and hence dissolving 
the drug in the lipid 
11 
No solubilizing agent is used The lipid core is prepared at the 
recrystallization temperature of the lipid 
The precipitation of drug is melted lipid 12 
The drug is dispersed in the lipid 
matrix 
Cooling the obtained dispersion results in 
partitioning the drug into the lipid phase 
Finally, the recrystallization of the lipid is 
done by further cooling 
13 
There is a strong interaction between 
drug and lipid  
The drug is concentrated in the outer shell The drug is concentrated in the core 14 
 
 
Fig. 1: Diagrammatic illustration of drug integration models of SLNs [11] 
 
 Homogenous matrix model  
Type I is generated from a solid solution of lipid and active 
constituent. The solid solution is obtained when SLNs are prepared 
by a cold homogenization technique without using a surfactant. A 
lipid mixture can be made with the active constituent in a 
molecularly dispersed form. Upon solidifying the lipid mixture, it is 
crushed in its solid form to reduce the accumulation of the drug in 
various parts of SLNs [12].  
 Drug enriched shell model 
SLN type II is produced using the hot high-pressure homogenization 
technique and applying a small concentration of the active 
ingredient in the lipid matrix. In the process of cooling the hot O/W 
nano-emulsion, the lipid is precipitated first. As a result, there is an 
increase in the concentration of the drug molecules, which remained 
in the melt [13]. Then; the outer shell is solidified containing both 
lipid and drug. The active constituent percentage contained in the 
outermost shell can be altered in a regulated shell design when the 
coenzyme is incorporated [14].  
 Drug enriched core model 
When the concentration of the active ingredient in the lipid melt is 
high and comparatively near saturation, the core model is 
developed. In this method, cooling Nano-emulsion leads to the 
precipitation of the drug due to super saturation at low 
temperatures. Further cooling leads to the precipitation of the 
melted lipid and surrounding the precipitated drug particles and the 
development of drug enriched core [14]. 
Advantages and disadvantages of SLNs as drug carrier  
Advantages of SLNs 
• The use of biodegradable lipids reduces the possibilities of 
severe and prolonged toxicity.  
• Enhancing the bioavailability of low water-soluble active 
constituents. 
• Enhancing the stability of chemically labile drugs through 
protection from the external environment. 
• SLNs have improved stability in comparison with other drug 
carriers as liposomes. 
• The high entrapment efficiency of the active constituents. 
• The possibility of lyophilisation.  
Disadvantages of SLN 
• The drug loading ability is poor.  
• Water content in the dispersions is comparatively high (70-99.9%). 
• The unpredictable tendency to gelation.  
• The unpredicted dynamics of polymeric changes. 
• Drug expulsion during storage after a polymeric transition. 
• The possibility of particle growth. 
Techniques for SLNs preparation  
The properties of SLNs are greatly influenced by the techniques used 
in their production. Among these properties are the following: the size 
of the particle, the drug loading ability, the drug release behavior, and 
the drug stability. Due to these effects, the efficacy of their preparation 
also depends on the method of preparation. Several methods are used 
for manufacturing finely distributed SLNs [15].  
 High shear homogenization (HSH) 
This method is a potent approach to SLNs preparation. For the large 
scale production of SLNs, HSH can be employed in contrast to other 
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methods. The hot and cold methods are the two methods of 
homogenization. In both methods, before the shear homogenization, 
the active constituents are melted or spread in the melted lipid. 
Nano-sized SLNs are obtained when the pressure of 100-2000 bar in 
the homogenizer causes the fluid to move in the narrow gap. The 
improved drug stability, Large-scale production, improved drug 
loading, and the lack of organic solvent are the advantages of 
homogenization [16, 17]. 
 Hot homogenization  
In this process, the homogenization process takes place at a 
temperature greater than the melting point of the lipid. The Pre-
emulsions are formed when drug-loaded lipid melt is dispersed in 
hot aqueous solution of surfactants using Ultra-Turrax (mixing 
device). As a result of the decreased viscosity due to high 
temperatures, the size of the particle becomes smaller (fig. 2). Three 
basic problems were reported for this method as follows: the 
difficulty of using thermolabile drug, the penetration of the drug into 
the aqueous phase during the homogenization process, and the 
complexity of the crystallization step of the Nano-emulsion, which 
may result in modification and/or super-cooled melts [18]. Remya 
and Damodharan prepared cilnidipine-loaded SLNs using the hot 
homogenization method [19]. 
 Cold homogenization 
In this approach, the drug is melted in the lipid melt, and after that, it is 
quickly cooled using liquid nitrogen or ice crystal. Milling leads to the 
production of nanoparticles in the range of 50-100 nm, which can be 
dispersed in a cold surfactant that produces a pre-suspension. High-
pressure homogenization (PHP) is used to split the nanoparticles into 
SLNs at the ambient temperature. All the main drawbacks of the hot 
homogenization approach are resolved by the cold homogenization 
procedure (fig. 2) [20]. Karami et al. prepared Superoxide dismutase-
loaded SLNs using the cold homogenization method [21]. 
 
 
Fig. 2: Cold and hot homogenization procedures [22] 
 
 Ultra-sonication or high-speed homogenization  
This technique is one of the techniques which are used to produce 
SLNs. In this technique, the aqueous phase containing a large 
quantity of surfactant is dispersed with the lipid phase, as shown in 
fig. 3. The large quantity of the surfactant is considered as a 
drawback. The inability to produce nanoparticles with a narrow size 
distribution, thereby giving rise to instability during storage, is also 
considered as a drawback for this technique. This method, unlike the 
hot and cold homogenization, makes use of simple instruments that 
are readily available almost in all laboratories [23, 24]. Swidan et al. 
prepared SLNs of Paclitaxel using this method [25]. Shelat et al. 
prepared curcuminoid-loaded SLNs to improve the oral 
bioavailability using the high-speed homogenization method [26]. 
 
 
Fig. 3: Ultra sonication technique [27] 
 
 Spray drying 
This method employs lipids with a high melting point (≥ 70 °C). It is 
an alternative to the lyophilization method (fig. 4). A better result is 
obtained when a 1% concentration of SLN is used in a suspension of 
trehalose in water, or 20% trehalose is used in the ethanol-water 
mixture [18].  
Wang et al. prepared ultra-fine powders of polysaccharide-coated 
SLN carriers using the innovative Nano-spray drying technique [28]. 
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Fig. 4: Spray drying technique [29] 
 
 Solvent emulsification-diffusion method 
As shown in fig. 5, in this technique, a water-immiscible organic 
solvent is employed to dissolve the solid lipid. The emulsion is 
formed by dispersing the lipid phase in an aqueous phase containing 
a surfactant. The organic solvent is allowed to evaporate from the 
emulsion at reduced pressure. As a result of organic solvent 
evaporation, the SLNs are prepared in the aqueous phase (by 
applying the lipid precipitation process in the aqueous phase). This 
process does not undergo thermal stress; however, the use of an 
organic solvent is considered as a disadvantage. The size of the 
particle differs according to the solid lipid and surfactant [30, 31]. 
Patravale and Mirani prepared SLNs-based gel for topical use using 
the solvent emulsification-diffusion method [32]. 
 Solvent evaporation method 
Cyclohexane, which is a water-immiscible organic solvent, is used to 
dissolve the solid lipid, and then it is emulsified with the aqueous 
phase. When the solvent is evaporated, nanoparticles dispersal is 
obtained by the deposition of the lipid in the aqueous phase by 
providing the nanoparticles of 25 nm mean size. By using high-
pressure homogenization, the lipid solution is emulsified in the 
aqueous phase (fig. 5). Under the reduced pressure of 40–60 m bar, 
cyclohexane was removed from the emulsion by evaporation [33]. 
Amasya et al. prepared 5-fluorouracil-loaded SLNs using the solvent 
evaporation method [34]. 
 Solvent-injection method 
In this method, the active ingredient and the lipid are dissolved in a 
water-soluble organic solvent such as isopropanol and ethanol. The 
solution is injected into water under stirring using a syringe needle. 
The lipid is converted into nanoparticles when it becomes in contact 
with water, resulting in entrapping the drug. The lipid type, the 
solvent applied, the surfactant, and the viscosity of the external 
phase are factors that determine the size of the particle (fig. 6). 
Leonardi et al. designed and prepared Ciprofloxacin Hydrochloride 
as SLNs using the solvent-injection method [36]. 
 
 
Fig. 5: Solvent emulsification-diffusion and evaporation technique [35] 
 
 Double emulsification method 
This method is derived from the emulsion solvent evaporation 
technique. This method is employed to produce SLNs loaded with 
hydrophilic drugs. In this method, the drug and emulsifying agents are 
existing in the aqueous internal phase of w/o/w double emulsion [38]. 
 Supercritical fluid extraction of emulsions (SFEE) 
Comparatively, this technique is novel for the preparation of SLNs. 
This technique uses carbon dioxide (a supercritical fluid) for 
removing the solvent from o/w emulsions (fig. 7). CO2 is a better 
choice; however, it cannot dissolve many drugs. Hence, the 
supercritical anti-solvent precipitation (SAS) can serve as a 
substitute for SFEE [39]. Couto et al. prepared Vitamin B2 in SLNs 
using supercritical CO2 [40]. 
 Membrane contractor method 
This method uses a membrane contractor for large scale production 
of SLN. In this method, the lipid phase is allowed to press through 
the membrane pores at a temperature above the lipid’s melting 
point. As a result, the lipid is extruded in the form of melted small 
droplets through the membrane pores. The aqueous phase circulates 
inside the membrane module and sweeps away the lipid droplets, 
which are formed at the pores outlet.  
The effect of process parameters (such as aqueous phase flow 
velocity, lipid phase pressure, aqueous phase, and lipid phase 
temperature, and size of the membrane pore) on the size of SLNs 
and the lipid phase extrusion is studied [41]. Also, the stability of 
vitamin-E-laden SLN was achieved (fig. 8). 
Qushawy et al. 
Int J App Pharm, Vol 12, Issue 1, 2020, 1-9 
5 
 
Fig. 6: Solvent-injection method [37] 
 
 
Fig. 7: Supercritical fluid technology technique [37] 
 
 
Fig. 8: Membrane contractor for SLN preparation [1] 
 
Secondary production methods 
 Freeze-drying 
In this method, water is removed to enhance the physicochemical 
stability of the system. In the pharmaceutical industry, freeze-
drying is the most frequently used method for converting 
solutions or suspensions into solids of high stability. Freeze-drying 
is also called lyophilization in which the frozen water is removed 
by sublimation. 
 Sterilization 
The SLNs dispersion, which is intended for parenteral 
administration, should be sterile. To achieve sterilization, filtration, 
autoclaving, aseptic production, and gamma irradiation are 
generally used for the production of sterile SLNs. The sterilization 
using autoclave is the most common and suitable process. However, 
the autoclaving is an excellent method for sterilization, where the 
elevated temperatures during sterilization can give rise to the 
aggregation of the SLNs [42]. 
Characterization of SLNs 
The use of advanced microscopic methods including Transmission 
Electron Microscopy (TEM), Scanning Electron Microscopy (SEM) 
and Atomic Force Microscopy (AFM) has made it possible to 
characterize nanoparticles according to their morphology, surface 
charge, and size. In vivo distribution, the nanoparticles and physical 
stability are influenced by the distribution of their size and the mean 
particle diameter and charge [12]. 
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 Particle size analysis and Zeta potential 
The physical stability of SLNs is determined by the size of the 
particle. The most common techniques for particle size 
determination are the Laser Diffraction (LD) and Photon Correlation 
Spectroscopy (PCS). The PCS, also called dynamic light scattering, is 
employed to determine the intensity of the scattered light resulting 
from the random motion of the particles. The PCS is employed to 
determine particle size within the range of 3 nm to 3 µm and laser 
diffraction is used to determine the particle size for the range of 100 
nm to 180 µm. Although the PCS is a good instrument for 
nanoparticle characterization, it can also be used for larger size 
determination of the micro-particles. The LD technique is based on 
the effect of the particle size on the diffraction. Smaller particles, 
compared to the large ones, produce stronger scattering with high 
diffraction angle [12]. 
Zeta meter or Zeta potential analyzer can be used for the 
determination of Zeta potential. For size determination and zeta 
potential determination, the dispersion of SLNs is first diluted 50-
fold with the primary dispersion preparation medium [43]. The 
increased value of zeta potential could give rise to the 
disaggregation of the particles. Zeta potential determination makes 
it possible to predict the storage stability of colloidal dispersion [44].  
 X-ray diffraction and differential scanning calorimeter 
(DSC) 
The geometric scattering of radiation from crystal planes within a 
solid allows the determination of the presence or absence of the 
former and thus permits the measurement of the degree of 
crystallinity. DSC can be applied to evaluate the properties and the 
degree of crystallinity of drugs in nanoparticles [45].  
 Electron microscopy 
For direct observation of nanoparticles, TEM, and SEM are employed 
[46]. The SEM is used for better morphological examination, and it 
has a small size limit of detection [12].  
 Atomic force microscopy (AFM)  
By using this approach, a probe tip with atomic-scale sharpness is 
re-established across a sample to create a topological map, which is 
based on the forces between the tip and the surface. The atomic 
force microscopy is a useful tool to obtain ultrahigh-resolution of the 
particles [45]. 
 Dynamic light scattering (DLS) 
The most common and the fastest methods for determining the 
particle size are the DLS and PCS. The DLS is commonly used for the 
size determination of Brownian nanoparticles in colloidal dispersion 
in the Nano and submicron range. Shining monochromatic light 
(laser) onto a solution of spherical particles (in case of random 
Brownian motion) leads to Doppler shift when the light hits the 
moving particles. As a result, the wavelength of the coming light is 
changed and it was revealed that this change is related to the size of 
the particle. The DLS is also useful for the determination of size 
distribution, the particle movement in the medium, the diffusion 
coefficient of the particle, and the use of the autocorrelation 
function. The PCS is the commonly applied method for the accurate 
determination of particle size and the distribution of size based on 
DLS [47].  
 Nuclear magnetic resonance (NMR) 
NMR can be used for both the qualitative nature and the size of 
nanoparticles’ measurement. The selection of the technique depends 
on the chemical shifting balances and the sensitivity to molecular 
flexibility to provide data about the physicochemical state of the 
constituent inside the nanoparticles [10]. 
 Acoustic methods 
Acoustic Spectroscopy is a technique that determines the particle 
size by measuring the attenuation of sound waves and applying the 
physical equation. The oscillating electric field created by the 
charged particle movement under the control of acoustic energy can 
be identified to provide information on the surface charge. 
 Surface charge 
The interaction of Nanoparticles with their biological environment 
and their electrostatic interaction with bioactive compounds are 
determined by the intensity and nature of the surface charge. The 
zeta potential is used to analyze the colloidal stability of the 
nanoparticles. The zeta potential is an indirect measurement of the 
surface charge. The determination of zeta potential makes it possible 
to predict the stability of the colloidal dispersion during storage. The 
high value of zeta potential, whether positive or negative values, 
ensures the stability of the colloidal particle and also ensures the 
absence of aggregations (table 2). The degree of surface 
hydrophobicity then can be estimated from the values of the zeta 
potential. The zeta potential can also give information on the nature 
of the drug to be encapsulated within the nanocapsule or absorbed 
on the surface [48]. 
 
Table 2: Characterization parameters of SLNs 
S. No.  Parameters Importance Methods References 
1 Size and Shape Determining skin penetration Photon correlation, Scanning electron microscope 
and Transmission electron microscope 
46 
2 Zeta potential The stability of particles Zeta potentiometer, Laser droplet anemometry 48 
3 Entrapment 
efficiency 
Suitability of method Ultracentrifugation 12 
4 Drug content The suitability of the method of preparation  UV, HPLC 6 
5 In vitro dissolution Determine drug release rate from particles. Under physiologic and sink conditions. 9 
 
Routes of administration of SLNs 
 Perioral administration forms of SLN 
The oral SLNs may be administered in the form of an aqueous 
dispersion or SLNs loaded in the traditional forms of solid dosage 
like tablets, capsules, or pellets. The improved bioavailability and 
extended plasma levels were reported after the perioral 
administration of cyclosporine containing lipid Nano dispersions to 
animals. Kaliamurthi and Selvaraj found that SLNs are good carriers 
for oral administration of anti-diabetic drugs [49]. Ansari et al. 
supported the oral bioavailability of insulin by formulating it as 
SLNs [50]. Mahajan et al. prepared stearic-acid-based SLNs of 
candesartan cilextil to improve the oral bioavailability [51].  
 Parenteral use 
Animals were injected intravenously with SLNs. The 
pharmacokinetic study of doxorubicin entrapped in SLN revealed 
the increased blood levels of the drug compared to the commercial 
drug suspension after intravenous administration in rats.  
About the body distribution, SLN was reported to increase drug 
concentrations in the lung, spleen, and brain, while the 
traditional form of drug leads to the distribution of the drug into 
the liver and kidneys. Also, the injection of the drug in the form 
of SLNs reduces the irritant effect caused in the case of micro 
particles. Chetoni et al. prepared tobramycin SLNs for 
intraocular delivery [52]. 
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 Transdermal application 
The dispersion of SLNs, which is prepared with low lipid content up 
to 5%, was reported to have a very small particle size. The direct 
application of the dispersion of SLNs to the skin is difficult due to the 
low lipid concentration and low viscosity of the dispersion. To 
facilitate the application of SLNs to the skin, it is preferred to be 
incorporated into the base of cream, ointment, or gel. For direct 
application of the dispersion of SLNs, the concentration of lipids 
should be increased to produce a semisolid system suitable for the 
application to the skin [53]. Gönüllü et al. prepared SLNs of 
lornoxicam for transdermal delivery [54]. 
 Topical administration 
SLNs are very attractive colloidal carrier systems for skin 
applications due to the numerous desirable effects on the skin. Since 
they are made up of non-irritant and nontoxic lipids, this makes 
them appropriate for use on damaged or irritated skin. Jain et al. 
designed SLNs for the topical delivery of an anti-fungal drug [55]. 
 Ophthalmic administration 
The preparation of ophthalmic drugs as SLNs increases their efficacy 
due to the mucoadhesive characteristics of SLNs, which increase the 
ocular retention time and hence increase the bioavailability. Gowda 
et al. studied the effect of SLNs on enhancing the ocular availability 
of ophthalmic drugs [56]. 
 Respiratory application 
The nebulization of SLNs carrying anti-tubercular drugs, anti-
asthmatic drugs, and anti-cancer was found to be effective in 
increasing drug bioavailability and decreasing the dosing rate for 
improving the pulmonary action. Rosière et al. prepared paclitaxel-
loaded SLNs with improved efficacy in the treatment of lung tumors 
when used as inhalers [57].  
Pharmaceutical applications of SLNs 
SLNs have numerous pharmaceutical applications which include:  
 Cancer treatment 
In recent years, various anticancer agents were compressed to SLNs 
and their in vitro, and in vivo efficiency were estimated.  
A) Targeting of anticancer drugs 
The extended-release of tamoxifen (an anticancer drug) is attained by 
preparing it as SLNs for intravenous administration in breast cancer. 
Also, the target effect of methotrexate and camptothecin to tumor tissue 
was accomplished with SLN loaded with the drug. Tupal et al. prepared 
doxorubicin-loaded SLNs for the treatment of skin cancer [58]. 
B) SLN in breast cancer and lymph node metastases 
Mitoxantrone SLN local injections were produced to decrease the 
toxicity and increase the safety and bioavailability of the drug. The 
efficacy of doxorubicin in the reduction of breast cancer cells was 
reported to be enhanced when prepared as SLNs [59]. Wang et al. 
studied the anticancer effects of resveratrol-loaded SLNs on human 
breast cancer cells [60]. 
 Antitubercular chemotherapy  
The preparation of anti-tubercular drugs such as rifampicin and 
isoniazid as SLNs leads to the reduction of the dosage regimen and 
the improvement of patient compliance [61]. Bhandari et al. 
succeeded in preparing isoniazid-SLNs to improve bioavailability 
and prolong the therapeutic effect and therefore reduce pulsatile 
plasma concentrations [62]. 
 SLN as a carrier for vaccines 
Adjuvants are used to improve immune response during 
vaccination. The safer novel subunit vaccines are less efficient in 
immunization, and for this reason, efficient adjuvants are needed. 
Emulsion systems of SLNs have been recently employed to use the 
adjuvant. This is O/W emulsions that are degraded in the body after 
administration [63]. 
 SLN for topical application 
SLNs are suitable colloidal transport systems for skin applications 
due to their numerous desirable effects on the skin. Recently, studies 
were carried out on SLNs with compounds such as ascorbyl 
palmitate, Vitamin E, retinol, clotrimazole, triptolide, nonsteroidal 
antiandrogen, tocopherol acetate and podophyllotoxin for topical 
application [64]. Kelidari et al. prepared spironolactone loaded SLNs 
for skin application [65]. 
 SLN for potential agriculture application 
Based on the previous study, it was found that when the volatile oil 
extracted from Artemisia arborescent L is incorporated into SLNS, it 
decreases the rapid evaporation compared to its incorporation into 
emulsions. This system is used in agriculture as an appropriate 
transporter of ecologically safe pesticides [12]. 
 Stealth nanoparticles 
This is a new system for drug-transport. It avoids the rapid 
clearance of the drug by the immune system. By using antibody-
labeled stealth lipobodies, previous researches approved the 
improved delivery to the unreachable sites of target tissue [66]. 
 SLNs for cosmetics 
SLNs have been used in the production of sunscreens and they act as 
an important carrier for molecular sunscreen and ultraviolet (UV) 
blocker. The in vivo study revealed that skin moisturization would 
be improved by 31% after four weeks when 4% of SLN is added to 
the conventional cream. SLNs have shown to be a controlled, 
innovative, occlusive, and topical release [67]. Wissing and Müller 
found that the efficacy of hydrating cream and sunscreen creams 
improved when prepared in the form of SLNs [68].  
CONCLUSION 
SLNs are attractive drug carriers and are considered as an 
alternative method for other colloidal dispersion systems. The SLNs 
represent a safe and effective carrier for the drug due to the 
biocompatibility of the used solid lipid. This article covered the 
different methods of preparation of SLNs, the effect of formulation 
variable on the characteristics of SLNs, the advantages and 
disadvantages of SLNs, the characterization of SLNs, the route of 
administration, and the pharmaceutical applications.  
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